<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60611">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02316886</url>
  </required_header>
  <id_info>
    <org_study_id>AMCCV2014-13</org_study_id>
    <nct_id>NCT02316886</nct_id>
  </id_info>
  <brief_title>The Preventive Implantation of Bioresorbable Vascular Scaffold on Functionally Insignificant Stenosis With Vulnerable Plaque Characteristics</brief_title>
  <acronym>PREVENT</acronym>
  <official_title>The Preventive Implantation of Bioresorbable Vascular Scaffold on Functionally Insignificant Stenosis With Vulnerable Plaque Characteristics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Jung Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Bioresorbable Vascular Scaffold(BVS)
      implantation on functionally insignificant coronary stenosis with vulnerable plaque reduce
      the incidence of the composite of cardiovascular death, nonfatal myocardial infarction, or
      unplanned rehospitalization due to unstable angina compared with optimal medical therapy
      alone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cardiovascular death</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Nonfatal myocardial infarction</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Unplanned hospitalization leading to unstable angina</measure>
    <time_frame>24 months</time_frame>
    <description>Unplanned hospitalization from unstable angina, regardless of repeat revascularization as adjudicated by the Clinical Event Committee (CEC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death from any causes</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure, defined as a composite of cardiovascular death, target vessel related myocardial infarction, or target vessel revascularization</measure>
    <time_frame>24 months</time_frame>
    <description>The composite of death, MI, and any TVR at a mean of 2 years follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The composite of death, myocardial infarction, and any repeat revascularization</measure>
    <time_frame>24 months</time_frame>
    <description>The composite of death, myocardial infarction, and any repeat revascularization at a mean of 2 years follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death and combinations of cardiac death with other components of MACE at each time point</measure>
    <time_frame>1 month</time_frame>
    <description>Cardiac death and combinations of cardiac death with other components of MACE at each time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death and combinations of cardiac death with other components of MACE at each time point</measure>
    <time_frame>6 months</time_frame>
    <description>Cardiac death and combinations of cardiac death with other components of MACE at each time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death and combinations of cardiac death with other components of MACE at each time point</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiac death and combinations of cardiac death with other components of MACE at each time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death and combinations of cardiac death with other components of MACE at each time point</measure>
    <time_frame>24 months</time_frame>
    <description>Cardiac death and combinations of cardiac death with other components of MACE at each time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-urgent revascularization procedures</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCS(Canadian Cardiovascular Society) angina class</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCS(Canadian Cardiovascular Society) angina class</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCS(Canadian Cardiovascular Society) angina class</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCS(Canadian Cardiovascular Society) angina class</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of anti-anginal medication at each point in time</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of anti-anginal medication at each point in time</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of anti-anginal medication at each point in time</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of anti-anginal medication at each point in time</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of non-urgent (repeat) revascularization at each point in time</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of non-urgent (repeat) revascularization at each point in time</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of non-urgent (repeat) revascularization at each point in time</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of non-urgent (repeat) revascularization at each point in time</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of any cerebrovascular event at each point in time</measure>
    <time_frame>1 month</time_frame>
    <description>Rate of any cerebrovascular event at each point in time as adjudicated by the Critical Event Committee (CEC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of any cerebrovascular event at each point in time</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of any cerebrovascular event at each point in time as adjudicated by the Critical Event Committee (CEC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of any cerebrovascular event at each point in time</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of any cerebrovascular event at each point in time as adjudicated by the Critical Event Committee (CEC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of any cerebrovascular event at each point in time</measure>
    <time_frame>24 months</time_frame>
    <description>Rate of any cerebrovascular event at each point in time as adjudicated by the Critical Event Committee (CEC).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Plaque, Atherosclerotic</condition>
  <arm_group>
    <arm_group_label>Bioresorbable Vascular Scaffold</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bioresorbable Vascular Scaffold+Optimal Medical Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal Medical Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Optimal Medical Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bioresorbable Vascular Scaffold</intervention_name>
    <description>Bioresorbable Vascular Scaffold + Optimal Medical treatment</description>
    <arm_group_label>Bioresorbable Vascular Scaffold</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optimal Medical treatment</intervention_name>
    <arm_group_label>Optimal Medical Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Symptomatic or asymptomatic coronary artery disease patients

          -  Patients having at least one stenosis with FFR(Fractional flow reserve) &gt;0.80 and
             meeting two of the following

               1. IVUS MLA(Intravascular ultrasound minimal luminal area)&lt;4mm2

               2. IVUS plaque burden&gt;70%

               3. Lipid-rich plaque on NIRS(Intracoronary Near-Infrared Spectroscopy) (defined as
                  maxLCBI4mm&gt;315)

               4. TCFA(thin-cap fibroatheroma) defined by OCT(fibrous cap thickness&lt;65µm and
                  arc&gt;90°) or VH-IVUS≥10% confluent NC with&gt;30° abutting to the lumen in 3
                  consecutive slices)

                    -  2 target vulnerable lesions

          -  Eligible for percutaneous coronary intervention with Absorb Bioresorbable Vascular
             Scaffold

          -  Willing and able to provide informed written consent

          -  Reference vessel diameter 2.75-4.0

          -  Lesion length ≤ 40

        Exclusion Criteria:

          -  Patients in whom the preferred treatment is CABG(Coronary artery bypass grafting)

          -  Stented lesion

          -  Bypass graft lesion

          -  The patients who have more than or equal to 3 target lesions

          -  2 target lesions in the same coronary territory

          -  Heavily calcified or angulated lesion

          -  Bifurcation lesion requiring 2 stenting technique

          -  Contraindication to or planned discontinuation of dual antiplatelet therapy within 1
             year

          -  Life expectancy less than 2 years

          -  Planned cardiac surgery or planned major non cardiac surgery

          -  Woman who are breastfeeding, pregnant or planning to become pregnant during the
             course of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregg Stone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jung-Min Ahn, MD</last_name>
    <email>drjmahn@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jung-Hee Ham, RN</last_name>
    <email>cvcrc5@amc.seoul.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alan C Yeung, MD</last_name>
      <email>ayeung@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Alan C Yeung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington, D.C</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ron Waksman, MD</last_name>
      <email>ron.waksman@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Ron Waksman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Mid America Heart Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David J Cohen, MD</last_name>
      <email>dcohen@saint-lukes.org</email>
    </contact>
    <investigator>
      <last_name>David J Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gregg W Stone, MD</last_name>
      <email>gstone@crf.org</email>
    </contact>
    <investigator>
      <last_name>Gregg W Stone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern Hospital , Victoria Australia</name>
      <address>
        <city>Epping</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Barlis, MD</last_name>
      <email>pbarlis@unimelb.edu.au</email>
    </contact>
    <investigator>
      <last_name>Peter Barlis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern Heart Clinic, Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nigel Jepson, MD</last_name>
      <email>Nigel.Jepson@ehc.com.au</email>
    </contact>
    <investigator>
      <last_name>Nigel Jepson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Kang-Yin Lee, MD</last_name>
      <email>kylee1991@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Michael Kang-Yin Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>EMO Centro Cuore Columbus, San Raffaele Hospital</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Colombo, MD</last_name>
      <email>colombo.antonio@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Colombo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aichi Medical University</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tetsuya Amano, MD</last_name>
      <email>amanotaha@yahoo.co.jp</email>
    </contact>
    <investigator>
      <last_name>Tetsuya Amano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kawasaki Medical School</name>
      <address>
        <city>Kurashiki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shiro Uemura, MD</last_name>
      <email>suemura@med.kawasaki-m.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Shiro Uemura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Takeshi Kimura, MD</last_name>
      <email>taketaka@kuhp.kyoto-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Takeshi Kimura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wakayama Medical University</name>
      <address>
        <city>Wakayama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Takashi Akasaka, MD</last_name>
      <email>akasat@wakayama-med.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Takashi Akasaka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung-jung Park, MD, PhD</last_name>
      <email>sjpark@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Seung-jung Park, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hyun-Sook Kim, MD</last_name>
      <email>heartsk@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Hyun-Sook Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tae-hyun Yang, MD</last_name>
      <email>yangthmd@naver.com</email>
    </contact>
    <investigator>
      <last_name>Tae-hyun Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gangwon National Univ. Hospital</name>
      <address>
        <city>Chuncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bong-Ki Lee, MD</last_name>
      <email>mdbklee@kangwon.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Bong-Ki Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Dae-jeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Si-Wan Choi, MD</last_name>
      <email>siwanc@cnu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Si-wan Choi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kee-Sik Kim, MD</last_name>
      <email>kks7379@cu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Kee-Sik Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang-Wook Nam, MD</last_name>
      <email>ncwcv@dsmc.or.kr</email>
    </contact>
    <investigator>
      <last_name>Chang-Wook Nam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Daejeon ST. Mary's Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sung-Ho Her, MD</last_name>
      <phone>82-042-220-9686</phone>
      <email>hhhsungho@naver.com</email>
    </contact>
    <investigator>
      <last_name>Sung-Ho Her, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Keun Ahn, MD</last_name>
      <email>cecilyk@chonnam.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Young-Keun Ahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae-Hoon Ahn, MD</last_name>
      <email>encore@gilhospital.com</email>
    </contact>
    <investigator>
      <last_name>Tae-Hoon Ahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ChonBuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jei-Keon Chae, MD</last_name>
      <email>jkchae@chonbuk.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Jei-Keon Chae, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dong-A Medical Center</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Moo-Hyun Kim, MD</last_name>
      <email>kmh60@damc.or.kr</email>
    </contact>
    <investigator>
      <last_name>Moo-Hyun Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo-yong Han, MD</last_name>
      <email>ichjy1@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Joo-yong Han, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bon-Kwon Koo, MD</last_name>
      <email>bkkoo@snu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ki-yuk Chang, MD</last_name>
      <email>kiyuk@catholic.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Ki-yuk Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bundang Cha Medical Center</name>
      <address>
        <city>Sungnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Won-jang Kim, MD</last_name>
      <email>mdwjkim@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Won-jang Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang hospital</name>
      <address>
        <city>Sungnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>In-Ho Chae, MD</last_name>
      <email>ihchae@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>In-Ho Chae, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Myeong-ho Yoon, MD</last_name>
      <email>yoonmh65@daum.net</email>
    </contact>
    <investigator>
      <last_name>Myeong-ho Yoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eun-Seok Shin, MD</last_name>
      <email>sesim98@yahoo.co.kr</email>
    </contact>
    <investigator>
      <last_name>Eun-Seok Shin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital and Canterbury DHB, University of Otago</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Smyth, MD</last_name>
      <email>david.smyth@cdhb.health.nz</email>
    </contact>
    <investigator>
      <last_name>David Smyth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National University Heart Center</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Hsien Li Kao, MD</last_name>
      <email>hsienli_kao@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Paul Hsien Li Kao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>China</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 13, 2016</lastchanged_date>
  <firstreceived_date>December 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Seung-Jung Park</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <keyword>Bioresorbable Vascular scaffold</keyword>
  <keyword>Vulnerable Plaque</keyword>
  <keyword>Insignificant Stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
